Combo therapy for advanced HER-2 breast cancer leads to slower progression
HER-2 positive breast cancer, accounting for approximately 25 to 30 percent of breast cancer patients, is considered to be a more aggressive form of cancer, often associated with poorer outcomes. Advances in treatment, however which include the monoclonal antibody Herceptin (trastuzumab) in conjunction with chemotherapy have allowed for better outcomes in women diagnosed with this variant of the disease when it is localized and can be surgically removed.
